Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

43.30 -0.53 (-1.22%)
Streaming Delayed Price Updated: 12:54 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
81 82 Next >
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
The Hot List: 3 AI Stocks Worth Buying on Weakness
Firms using AI directly can be great picks for long-term investors, such as these three AI stocks to buy on weakness. 
Via InvestorPlace
Topics Artificial Intelligence
Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
From Bristol Myers Squibb
Via Business Wire
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
 
Via Benzinga
How Is The Market Feeling About Bristol-Myers Squibb?
 
Via Benzinga
Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb
 
Via Benzinga
Large US Drug Makers Highlight Indian Market For Their Blockbuster Drugs Including For Weight Loss
Eli Lilly's CEO, David Ricks, outlines plans to launch the obesity drug Tirzepatide in India next year, presenting opportunities amid competition from Novo Nordisk. Bristol Myers Squibb expands its R&D... 
Via Benzinga
Bristol Myers Squibb to Participate in the TD Cowen 44th Annual Health Care Conference
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
From Bristol Myers Squibb
Via Business Wire
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings. 
Via InvestorPlace
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
From Bristol Myers Squibb
Via Business Wire
Mental Health Mavericks: 3 Stocks Changing the Game
Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money. 
Via InvestorPlace
The 3 Best Stocks Beginning Investors Can Buy: February 2024
Starting your investment journey? Navigate the market with confidence! Discover 3 stocks for beginning investors in this article. 
Via InvestorPlace
Got $5,000? These 3 Stocks Are Dirt Cheap Buys With Plenty of Upside
Shares of these companies are trading at sizable earnings discounts. 
Via The Motley Fool
Top Cannabis Appointments You Should Know About: Aurora's New CFO And Other Changes
Cannabis multi-state operator Cresco Labs kicked off February by announcing the promotion of Greg Butler to the position of president. Tom Shuman, a CPG sales and marketing veteran, agreed to serve as... 
Via Benzinga
Topics Cannabis
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI® (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or...
From Bristol Myers Squibb
Via Business Wire
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
Patience will be rewarded with these stocks. 
Via The Motley Fool
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts. 
Via InvestorPlace
Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC
From Bristol Myers Squibb
Via Business Wire
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
From Bristol Myers Squibb
Via Business Wire
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
From FN Media Group LLC
Via GlobeNewswire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
A Look At Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. 
Via Talk Markets
Topics ETFs
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings, Inc. (Nasdaq – ZFOX), RayzeBio, Inc. (Nasdaq – RYZB)
From Brodsky & Smith LLC
Via GlobeNewswire
7 Dividend Stocks to Buy at a 52-Week Low
Each of these dividend stocks has been down sharply in the last 12 months but has fundamental reasons that support a turnaround. 
Via InvestorPlace
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
From Bristol Myers Squibb
Via Business Wire
Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare
 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
81 82 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS